NO20075618L - Novel compounds as GLP-1 Agonists - Google Patents

Novel compounds as GLP-1 Agonists

Info

Publication number
NO20075618L
NO20075618L NO20075618A NO20075618A NO20075618L NO 20075618 L NO20075618 L NO 20075618L NO 20075618 A NO20075618 A NO 20075618A NO 20075618 A NO20075618 A NO 20075618A NO 20075618 L NO20075618 L NO 20075618L
Authority
NO
Norway
Prior art keywords
glp
agonists
novel compounds
compounds
diabetes
Prior art date
Application number
NO20075618A
Other languages
Norwegian (no)
Inventor
Braj Bhushan Lohray
Vidya Bhushan Lohray
Rajesh Bahekar
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of NO20075618L publication Critical patent/NO20075618L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Det beskrives en gruppe nye peptidomimetika som er nyttige for behandling av diabetes. Disse forbindelser er definert ved den generelle formel (I). A-X1-S1-Y-S2-X2-B (I)A group of novel peptidomimetics useful for the treatment of diabetes is described. These compounds are defined by the general formula (I). A-X1-S1-Y-S2-X2-B (I)

NO20075618A 2005-05-05 2007-11-06 Novel compounds as GLP-1 Agonists NO20075618L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN558MU2005 2005-05-05
IN645MU2005 2005-05-31
PCT/IN2006/000154 WO2007017892A2 (en) 2005-05-05 2006-05-04 Novel compounds as glp-i agonists

Publications (1)

Publication Number Publication Date
NO20075618L true NO20075618L (en) 2008-01-30

Family

ID=37727716

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075618A NO20075618L (en) 2005-05-05 2007-11-06 Novel compounds as GLP-1 Agonists

Country Status (12)

Country Link
EP (1) EP1891106A2 (en)
JP (1) JP2008540402A (en)
KR (1) KR20080021636A (en)
AP (1) AP2007004227A0 (en)
AU (1) AU2006277557A1 (en)
BR (1) BRPI0612471A2 (en)
CA (1) CA2606894A1 (en)
EA (1) EA200702419A1 (en)
IL (1) IL187105A0 (en)
MX (1) MX2007013655A (en)
NO (1) NO20075618L (en)
WO (1) WO2007017892A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
AU2007323035B2 (en) * 2006-10-03 2011-11-24 Cadila Healthcare Limited Antidiabetic compounds
RU2010128247A (en) * 2007-12-11 2012-01-20 Ф.Хоффманн-Ля Рош Аг (Ch) SYNTHESIS OF INSULINOTROPIC PEPTIDES USING COMBINED SOLID-PHASE AND SOLUTION METHODS
MX2010006287A (en) * 2007-12-11 2010-10-26 Cadila Healthcare Ltd Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities.
SG175411A1 (en) * 2009-05-01 2011-12-29 Hoffmann La Roche Insulinotropic peptide synthesis using solid and solution phase combination techniques
CN101891823B (en) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 Exendin-4 and analog fusion protein thereof
JP6480872B2 (en) 2013-02-15 2019-03-13 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Insulinotropic polypeptide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
GB0024428D0 (en) * 2000-10-05 2000-11-22 King S College Absorption enhancers
AU2002317599B2 (en) * 2001-07-31 2008-04-03 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GLP-1 exendin-4 peptide analogs and uses thereof
US7238671B2 (en) * 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
WO2003058203A2 (en) * 2002-01-08 2003-07-17 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
EP1718665B1 (en) * 2004-02-11 2013-04-10 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
TW200611704A (en) * 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
DE102004043153B4 (en) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Invention relating to GLP-1 and exendin

Also Published As

Publication number Publication date
EP1891106A2 (en) 2008-02-27
MX2007013655A (en) 2008-01-24
JP2008540402A (en) 2008-11-20
AP2007004227A0 (en) 2007-12-31
WO2007017892A2 (en) 2007-02-15
EA200702419A1 (en) 2008-04-28
CA2606894A1 (en) 2007-02-15
IL187105A0 (en) 2008-02-09
KR20080021636A (en) 2008-03-07
WO2007017892A3 (en) 2007-09-20
BRPI0612471A2 (en) 2016-09-06
AU2006277557A1 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
NO20075618L (en) Novel compounds as GLP-1 Agonists
EA201101004A1 (en) FUNCTIONAL COMPOSITION
UY29612A1 (en) CHEMICAL COMPOUNDS II
NO20075809L (en) DNA-PK inhibitors
NO20065613L (en) 3-carbamoyl-2-pyridonderivat.
EA200970605A1 (en) MAPK / ERK KINAZ INHIBITORS
TW200510381A (en) Novel 2-pyridinecarboxamide derivatives
UY30371A1 (en) CHEMICAL COMPOUNDS
CY1109911T1 (en) PYRROLOVENZODIAZEPINES
NO20080942L (en) Amino-5- [4- (difluoromethoxy) phenyl] -5-phenylimidazolone compounds as inhibitors of beta-secretase (BACE)
NO20084783L (en) Synthesis of acylaminoalkenylenamides useful as substance P antagonists
NO20082116L (en) Chemical process for preparing an amido-phenoxybenzoic acid compound
NO20084583L (en) Macrocyclic kinase inhibitors
MY153045A (en) Oxopyrazine derivative and herbicide
NO20091599L (en) Chemical connections
NI200900151A (en) NEW PROCEDURE FOR THE SYNTHESIS OF AGOMELATIN.
GEP20125512B (en) Process for synthesis of agomelatin
ATE411994T1 (en) PREPARATION OF A HIGH PURITY SUBSTITUTED QUINOXALINE
NO20082209L (en) Homo and heterocyclic compounds useful as CETP inhibitors
NO20091746L (en) New diphenyllazetidinone substituted with piperazine-1-sulfonic acid with improved pharmacological properties
HK1164114A1 (en) Antidepressant containing heterocyclic compound having specific structure
NO20074739L (en) Amide derivatives such as ion channel ligands and pharmaceutical compositions and methods for using the same
DE602005011784D1 (en) PYRAZOLOÄ4,3-DÜPYRIMIDINE
TW200710084A (en) Process for the synthesis of organic compounds
BRPI0607085A2 (en) heterocyclic oxime derivatives, their preparation process and their use as hypoglycemic and hypolipemic agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application